Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Other financing activities (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Other financing activities for 13 consecutive years, with $4000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Other financing activities fell 99.83% to $4000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $1.6 million, a 39.71% decrease, with the full-year FY2025 number at $1.6 million, down 39.71% from a year prior.
  • Other financing activities was $4000.0 for Q4 2025 at Anika Therapeutics, down from $13000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $2.3 million in Q4 2024 to a low of -$528000.0 in Q4 2021.
  • A 5-year average of $386900.0 and a median of $48000.0 in 2022 define the central range for Other financing activities.
  • Peak YoY movement for Other financing activities: tumbled 140.9% in 2021, then surged 6278.26% in 2025.
  • Anika Therapeutics' Other financing activities stood at -$528000.0 in 2021, then soared by 256.82% to $828000.0 in 2022, then skyrocketed by 142.51% to $2.0 million in 2023, then increased by 16.98% to $2.3 million in 2024, then plummeted by 99.83% to $4000.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Other financing activities are $4000.0 (Q4 2025), $13000.0 (Q3 2025), and $83000.0 (Q2 2025).